Download this document in MS Word format


State of Vermont

House of Representatives

Montpelier, Vermont

Joint House Resolution

J.R.H.  6

     Joint resolution urging the Food and Drug Administration and the Multiple Sclerosis Society to study the efficacy of low dose naltrexone as a multiple sclerosis medication

     Offered by:  Representative Obuchowski of Rockingham

     Whereas, multiple sclerosis (MS) is an inflammatory disease of the central nervous system (CNS) that damages the myelin sheath or insulating material that surrounds the nerve fibers in the brain, spinal cord, and optic nerves, and

     Whereas, MS is characterized by attacks known as“flare-ups” or exacerbations which may be associated with plaques that prevent conduction of nerve impulses in the CNS, and

     Whereas, MS is most likely to occur in persons ages 20 to 40, and women are two to three times as likely as men to contract the disease, and

     Whereas, no two cases of MS are identical, and although some persons go for years with no symptoms, lesions may still be forming in the CNS, and

     Whereas, in the United States, it is estimated approximately 350,000 individuals live with MS, and nearly 200 cases are diagnosed each week, and

     Whereas, Vermont has the highest percentage of MS cases per capita of any state in the nation, and

     Whereas, there is a variety of approved drugs for treating MS that have varying degrees of success, and

     Whereas, one drug that is not currently approved for MS treatment, but in private use has reportedly been effective, is low dose naltrexone (LDN), and

     Whereas, although neither the United States Food and Drug Administration (FDA) nor the National Multiple Sclerosis Society has conducted any official trials on the effectiveness of LDN, unofficial trials have shown a high degree of success in arresting the disease’s progression, although problems have occurred in individuals who are exposed to undue fatigue, heat or a febrile illness, and

Whereas, despite this caveat, the overwhelmingly positive reports on the impact of LDN for MS patients merits official clinical trials under the auspices of the National Multiple Sclerosis Society, now therefore be it



Resolved by the Senate and House of Representatives:

That the General Assembly urges both the United States Food and Drug Administration and the Multiple Sclerosis Society to conduct scientifically valid clinical trials to assess the effectiveness and ramifications of low dose naltrexone as a medication for treating multiple sclerosis, and be it further

Resolved:  That the United States Congress appropriate funds to support the federal research, and be it further

Resolved:  That a copy of this resolution be sent to Acting FDA Commissioner Dr. Lester Crawford, to President and Chief Executive Officer of the National Multiple Sclerosis Society, Michael Dugan, to the members of the Vermont Congressional Delegation, and to Seth and Candi Sawyer in Westminster.




____________________________              Attested to:

Gaye R. Symington

Speaker of the House


____________________________              ____________________________

Brian E. Dubie                                             Donald G. Milne

President of the Senate                               Clerk, House of Representatives





Published by:

The Vermont General Assembly
115 State Street
Montpelier, Vermont